The ThermiRF temperature-controlled radiofrequency system has gained a new indication to treat vulvovaginal laxity, according to a statement from ThermiGen.
The ThermiVa system stimulates the remodeling of dermal and epidermal tissue in the vulvovaginal region, according to the statement. While symptoms of vulvovaginal laxity vary, numerous adverse effects may occur, including a reduction in lubrication, sexual function and satisfaction, along with dyspareunia and urinary incontinence associated with stress. The ThermiVa treatment can be administered in an office setting, with an electrode capable of treating internal and external structures comfortably, according to experts at ThermiGen.
The indication comes on the heels of a study showing that 93% of women reported improved vulvovaginal laxity after treatment with the system. Sexual functioning and satisfaction as assessed by the Female Sexual Function Index also improved in the cohort. Improvements were reported for all domains, including desire, arousal, lubrication, orgasm, satisfaction, and pain. – by Rob Volansky